Cumberland Pharmaceuticals Ownership

CPIX Stock  USD 1.06  0.02  1.85%   
The market capitalization of Cumberland Pharmaceuticals is $15.17 Million. Cumberland Pharmaceuticals retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 
Shares in Circulation  
First Issued
2006-03-31
Previous Quarter
14.1 M
Current Value
14.1 M
Avarage Shares Outstanding
17 M
Quarterly Volatility
2.7 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Cumberland Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Cumberland Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Dividends Paid is likely to drop to about 147.9 K in 2024. Dividend Paid And Capex Coverage Ratio is likely to drop to 10.31 in 2024. Common Stock Shares Outstanding is likely to drop to about 13.5 M in 2024. Net Loss is likely to rise to about (4.8 M) in 2024.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.

Cumberland Stock Ownership Analysis

About 45.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.62. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cumberland Pharmaceuticals recorded a loss per share of 0.76. The entity last dividend was issued on the 29th of October 2010. The firm had 2:1 split on the 6th of July 2007. Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee. Cumberland Pharmaceu operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 83 people. For more info on Cumberland Pharmaceuticals please contact the company at 615 255 0068 or go to https://www.cumberlandpharma.com.
Besides selling stocks to institutional investors, Cumberland Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cumberland Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cumberland Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Cumberland Pharmaceuticals Quarterly Liabilities And Stockholders Equity

76.75 Million

About 45.0% of Cumberland Pharmaceuticals are currently held by insiders. Unlike Cumberland Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cumberland Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cumberland Pharmaceuticals' insider trades

Cumberland Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Cumberland Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cumberland Pharmaceuticals backward and forwards among themselves. Cumberland Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Cumberland Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Ubs Group Ag2024-06-30
6.9 K
Tower Research Capital Llc2024-06-30
6.6 K
Morgan Stanley - Brokerage Accounts2024-06-30
5.3 K
Oakworth Capital Inc2024-09-30
3.1 K
Citadel Advisors Llc2024-06-30
834
Advisor Group Holdings, Inc.2024-06-30
100.0
Bank Of America Corp2024-06-30
67.0
Royal Bank Of Canada2024-06-30
47.0
Jpmorgan Chase & Co2024-06-30
20.0
Renaissance Technologies Corp2024-09-30
528.2 K
Vanguard Group Inc2024-09-30
374.3 K
Note, although Cumberland Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cumberland Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cumberland Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cumberland Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cumberland Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Krogulski Kenneth over three weeks ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.32 subject to Rule 16b-3
 
Krogulski Kenneth over three weeks ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.24 subject to Rule 16b-3
 
Krogulski Kenneth over three weeks ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.25 subject to Rule 16b-3
 
Krogulski Kenneth over three weeks ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.23 subject to Rule 16b-3
 
Krogulski Kenneth over three weeks ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.24 subject to Rule 16b-3
 
Krogulski Kenneth over three weeks ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.26 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.25 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.25 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.28 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.3 subject to Rule 16b-3
 
Young Caroline over a month ago
Acquisition by Young Caroline of tradable shares of Cumberland Pharmaceuticals at 1.36 subject to Rule 16b-3
 
Krogulski Kenneth over a month ago
Acquisition by Krogulski Kenneth of 309 shares of Cumberland Pharmaceuticals at 1.36 subject to Rule 16b-3

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cumberland Stock Analysis

When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.